Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Mitchell
News Release
Impact of COVID-19 on Workers' Compensation and Auto Casualty Industries
Auto Casualty
Article
Five Questions With Shahin Hatamian on How to Incorporate More Automation in the Claims Process
We sat down with Mitchell Senior Vice President, Shahin Hatamian, to discuss how claims organizations can utilize automation to help expedite proce
Mitchell
News Release
State-By-State Pharmacy Rule Updates Related to COVID-19
In the wake of COVID-19, a number of states have begun relaxing time frames and other rules around the provision of care for their citizens, includ
Auto Casualty
Article
Impact of COVID-19 on Workers’ Compensation and Auto Casualty Industries
As the COVID-19 pandemic continues worldwide, our daily lives have changed significantly.
Mitchell
News Release
Washington State Updates Workers' Compensation Drug Formulary
The Washington State Department of Labor and Industries adopted updates to its workers' compensation drug formulary.
Mitchell
News Release
New York Updates Workers' Comp Drug Formulary
The New York State Workers' Compensation Board announced updates to its drug formulary, effective April 1, 2020.